Cargando…

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon

PURPOSE: HBsAg clearance represents clinical cure for patients with hepatitis B, but remains difficult to obtain for most HBV-infected patients. Recent studies have shown that inactive HBsAg carriers treated with pegylated interferon can achieve higher clinical cure rates, which may imply that the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong, Liang, Shan, Liu, Lili, Zhou, Daqiong, Liu, Yali, Zhang, Yang, Chen, Xinyue, Zhang, Jing, Cao, Zhenhuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822570/
https://www.ncbi.nlm.nih.gov/pubmed/36618361
http://dx.doi.org/10.3389/fimmu.2022.1091786
_version_ 1784865976142004224
author Li, Hong
Liang, Shan
Liu, Lili
Zhou, Daqiong
Liu, Yali
Zhang, Yang
Chen, Xinyue
Zhang, Jing
Cao, Zhenhuan
author_facet Li, Hong
Liang, Shan
Liu, Lili
Zhou, Daqiong
Liu, Yali
Zhang, Yang
Chen, Xinyue
Zhang, Jing
Cao, Zhenhuan
author_sort Li, Hong
collection PubMed
description PURPOSE: HBsAg clearance represents clinical cure for patients with hepatitis B, but remains difficult to obtain for most HBV-infected patients. Recent studies have shown that inactive HBsAg carriers treated with pegylated interferon can achieve higher clinical cure rates, which may imply that the lower the baseline HBsAg quantification, the higher HBsAg clearance rate. Therefore, this study further investigated the HBsAg clearance rate in inactive HBsAg carriers with low level of HBsAg (<200 IU/ml) treated with pegylated interferon. METHODS: This is a prospective cohort study. Inactive HBsAg carriers with HBsAg<200 IU/ml were divided into treatment and control groups. Pegylated interferon was administered to the patients in therapeutic group for 96 weeks. The patients in control group underwent 96 weeks of observation without any anti-viral treatment. All patients were tested for HBsAg, anti-HBs, HBV DNA, liver function, blood count, thyroid function, thyroid antibodies and autoantibodies at baseline, week 12, 24, 36, 48, 60, 72, 84 and 96. Controlled attenuation parameter (CAP) and liver stiffness measure (LSM) were evaluated at baseline and week 96. Patients were classified into no steatosis, mild steatosis, moderate steatosis and severe steatosis according to the value of CAP. RESULTS: A total of 174 inactive HBsAg carriers with HBsAg<200IU/ml were enrolled, including 84 in the treatment group and 90 in the control group. In the treatment group, HBsAg clearance rate was 30.77% (24/78) at week 48, and increased to 57.69% (45/78) at week 96. HBsAg clearance occurred in 2 patients with a clearance rate of 2.27% (2/88) in control group, The HBsAg clearance rate of the treatment group was significantly higher than that of the control group (P<0.001). HBsAg clearance was significantly higher in patients with moderate steatosis than in those without steatosis (74.07% vs. 48.15%, p=0.008) at week 96. CONCLUSION: High HBsAg clearance rate could be obtained for inactive HBsAg carriers with HBsAg< 200 IU/ml treated with peginterferons. Inactive HBsAg carriers with moderate hepatic steatosis are more sensitive for the treatment.
format Online
Article
Text
id pubmed-9822570
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98225702023-01-07 Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon Li, Hong Liang, Shan Liu, Lili Zhou, Daqiong Liu, Yali Zhang, Yang Chen, Xinyue Zhang, Jing Cao, Zhenhuan Front Immunol Immunology PURPOSE: HBsAg clearance represents clinical cure for patients with hepatitis B, but remains difficult to obtain for most HBV-infected patients. Recent studies have shown that inactive HBsAg carriers treated with pegylated interferon can achieve higher clinical cure rates, which may imply that the lower the baseline HBsAg quantification, the higher HBsAg clearance rate. Therefore, this study further investigated the HBsAg clearance rate in inactive HBsAg carriers with low level of HBsAg (<200 IU/ml) treated with pegylated interferon. METHODS: This is a prospective cohort study. Inactive HBsAg carriers with HBsAg<200 IU/ml were divided into treatment and control groups. Pegylated interferon was administered to the patients in therapeutic group for 96 weeks. The patients in control group underwent 96 weeks of observation without any anti-viral treatment. All patients were tested for HBsAg, anti-HBs, HBV DNA, liver function, blood count, thyroid function, thyroid antibodies and autoantibodies at baseline, week 12, 24, 36, 48, 60, 72, 84 and 96. Controlled attenuation parameter (CAP) and liver stiffness measure (LSM) were evaluated at baseline and week 96. Patients were classified into no steatosis, mild steatosis, moderate steatosis and severe steatosis according to the value of CAP. RESULTS: A total of 174 inactive HBsAg carriers with HBsAg<200IU/ml were enrolled, including 84 in the treatment group and 90 in the control group. In the treatment group, HBsAg clearance rate was 30.77% (24/78) at week 48, and increased to 57.69% (45/78) at week 96. HBsAg clearance occurred in 2 patients with a clearance rate of 2.27% (2/88) in control group, The HBsAg clearance rate of the treatment group was significantly higher than that of the control group (P<0.001). HBsAg clearance was significantly higher in patients with moderate steatosis than in those without steatosis (74.07% vs. 48.15%, p=0.008) at week 96. CONCLUSION: High HBsAg clearance rate could be obtained for inactive HBsAg carriers with HBsAg< 200 IU/ml treated with peginterferons. Inactive HBsAg carriers with moderate hepatic steatosis are more sensitive for the treatment. Frontiers Media S.A. 2022-12-23 /pmc/articles/PMC9822570/ /pubmed/36618361 http://dx.doi.org/10.3389/fimmu.2022.1091786 Text en Copyright © 2022 Li, Liang, Liu, Zhou, Liu, Zhang, Chen, Zhang and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Hong
Liang, Shan
Liu, Lili
Zhou, Daqiong
Liu, Yali
Zhang, Yang
Chen, Xinyue
Zhang, Jing
Cao, Zhenhuan
Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
title Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
title_full Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
title_fullStr Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
title_full_unstemmed Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
title_short Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
title_sort clinical cure rate of inactive hbsag carriers with hbsag <200 iu/ml treated with pegylated interferon
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822570/
https://www.ncbi.nlm.nih.gov/pubmed/36618361
http://dx.doi.org/10.3389/fimmu.2022.1091786
work_keys_str_mv AT lihong clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT liangshan clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT liulili clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT zhoudaqiong clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT liuyali clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT zhangyang clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT chenxinyue clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT zhangjing clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon
AT caozhenhuan clinicalcurerateofinactivehbsagcarrierswithhbsag200iumltreatedwithpegylatedinterferon